Stem Cell-Derived Microglia Differentiation via Wnt Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating human microglial cells in vitro do not accurately follow the developmental paradigm of primitive hematopoiesis, leading to difficulties in obtaining cells that accurately model human microglia-related disorders, as they often start from peripheral monocytes or use embryoid body approaches that are not pre-patterned for primitive hematopoiesis.
Innovation Solution
A method involving Wnt inhibition and activation to generate KDR+CD235a+ primitive hematopoietic precursors, followed by differentiation into microglial cells through culturing with neurons, which recapitulates yolk sac primitive hematopoiesis and results in cells expressing microglial markers, thereby accurately modeling human microglia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human primary microglia are obtained from post-mortem tissue, then the cells are authentic human microglia, but they are expensive, hard to obtain, and do not proliferate in culture
Solution Approach 1:
The patent uses hPSCs (human pluripotent stem cells) as a preliminary source that can be expanded and differentiated in advance to generate authentic human microglia. This preliminary action allows researchers to obtain sufficient numbers of authentic microglia for experimentation without relying on scarce post-mortem tissue samples.
Solution Approach 2:
The patent creates an in vitro model that copies the authentic human microglia from hPSCs. These hPSC-derived microglia replicate the key characteristics, gene expressions, and functions of primary human microglia, providing a reliable surrogate for research purposes.
2Ease of manufacture
If existing in vitro methods start from peripheral monocytes or use embryoid body approaches, then the methods are easier to implement, but they do not accurately follow the developmental paradigm of primitive hematopoiesis
Solution Approach 1:
The patent employs specific parameter changes in the differentiation protocol, including precise timing of Wnt pathway modulation (activation followed by inhibition), controlled cytokine exposure (M-CSF, IL-34), and staged culture conditions. These parameter changes guide hPSCs through the correct developmental trajectory to generate authentic microglia while maintaining protocol feasibility.
Solution Approach 2:
The differentiation process is segmented into distinct stages: mesoderm induction, primitive hematopoiesis activation, microglial lineage commitment, and maturation. Each stage has specific molecular cues and timeframes, allowing researchers to control and optimize each step while following the natural developmental paradigm.
3Ease of manufacture
If human immortalized microglial cell lines are used, then the cells are easy to obtain and culture, but they do not share key genes with primary microglia
Solution Approach 1:
The patent generates hPSC-derived microglia that copy the genetic and functional characteristics of primary human microglia. These cells maintain key microglial-specific gene expressions (TMEM119, P2RY12, SALL1, CX3CR1) and functional properties, providing an accurate model that is easier to obtain and culture than primary cells.
Data Source
AI summary
The present disclosure relates to methods for generating microglial cells derived from stem cells (e.g., human stem cells), microglial cells obtained from such methods and compositions comprising thereof, and uses of said microglial cells for disease modeling and for treating microglia related disorders.